PUBLIC LAW 106-310—OCT. 17, 2000 114 STAT. 1237 (1) REQUIREMENT.—The Secretary of Health and Human Services shall, in consultation with the Institute of Medicine of the National Academy of Sciences, conduct a study on the development of medications for the treatment of addiction to amphetamine and methamphetamine. (2) REPORT.— Not later than 9 months after the date of Deadline, the enactment of this Act, the Secretary shall submit to the Committees on the Judiciary of the Senate and House of Representatives a report on the results of the study conducted under paragraph (1). (b) AUTHORIZATION OF APPROPRIATIONS. —T here are hereby authorized to be appropriated for the Department of Health and Human Services for fiscal year 2000 such sums as may be necessary to meet the requirements of subsection (a). PART IV—REPORTS SEC. 3641. REPORTS ON CONSUMPTION OF METHAMPHETAMINE AND 42 USC 290aa-4 OTHER ILLICIT DRUGS IN RLTRAL AREAS, METROPOLITAN note. AREAS, AND CONSOLIDATED METROPOLITAN AREAS. The Secretary of Health and Human Services shall include in each National Household Survey on Drug Abuse appropriate prevalence data and information on the consumption of methamphetamine and other illicit drugs in rural areas, metropolitan areas, and consolidated metropolitan areas. SEC. 3642. REPORT ON DIVERSION OF ORDINARY, OVER-THE -COUNTER 21 USC 802 note. PSEUDOEPHEDRINE AND PHENYLPROPANOLAMINE PRODUCTS. (a) STUDY.— The Attorney General shall conduct a study of the use of ordinary, over-the-counter pseudoephedrine and phenylpropanolamine products in the clandestine production of illicit drugs. Sources of data for the study shall include the following: (1) Information from Federal, State, and local clandestine laboratory seizures and related investigations identifying the source, type, or brand of drug products being utilized and how they were obtained for the illicit production of methamphetamine and amphetamine. (2) Information submitted voluntarily from the pharmaceutical and retail industries involved in the manufacture, distribution, and sale of drug products containing ephedrine, pseudoephedrine, and phenylpropanolamine, including information on changes in the pattern, volume, or both, of sales of ordinary, over-the-counter pseudoephedrine and phenylpropanolamine products. (b) REPORT.— (1) REQUIREMENT.— Not later than 1 year after the date Deadline, of the enactment of this Act, the Attorney General shall submit to Congress a report on the study conducted under subsection (a). (2) ELEMENTS.— The report shall include— (A) the findings of the Attorney General as a result of the study; and (B) such recommendations on the need to establish additional measures to prevent diversion of ordinary, overthe-counter pseudoephedrine and phenylpropanolamine (such as a threshold on ordinary, over-the-counter
�
